Health Care

AstraZeneca is hoping to use its growing oncology pipeline, including a number of recent positive trial results, to fend off a takeover bid from rival Pfizer. 

Eli Lilly lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis.

AstraZeneca's chief executive said his company's board would consider a compelling offer from Pfizer, despite turning down previous offers from the firm.

Valeant plans to unveil an improved offer for Botox maker Allergan later this month, as the Canadian drug company seeks to rally shareholder support for a buyout.

Merck agreed to sell its consumer-care unit to German pharmaceutical giant Bayer for $14.2 billion, continuing a flurry of healthcare deals.

The pharmaceutical giant posted 1Q profits per share that beat the Street by two cents while revenue came in below expectations. Gloomy China Data Weigh on U.S. Stock Futures | Apple on Medical Tech Hiring Spree

CVS Caremark reported an 18% increase in its first-quarter earnings, as strength in the company's pharmacy services business lifted revenue.

AstraZeneca turned down a sweetened buyout offer of $106.4 billion from rival drug giant Pfizer, thwarting a move that would have created the world’s largest pharmaceutical company.

Botox-maker Allergan is reportedly hunting for a white knight after Valeant made a hostile buyout offer backed by Bill Ackman. 

Pfizer said Monday it made a nearly $100 billion bid to buy AstraZeneca earlier this year, and approached the firm earlier this month to resume talks. 

The medical-device maker said it would acquire orthopedic products company Biomet in a deal valued at about $13.35 billion.

Pharmaceutical companies have been announcing deals at breakneck speeds this year in what analysts say is an attempt to hedge risk and hike profits.

Amgen's first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.

Novartis said it will swap assets with GlaxoSmithKline and sell its animal health arm in a bid to simplify its business.

Johnson & Johnson's first-quarter profit surged 35%, as sales growth in its pharmaceutical business helped the healthcare giant beat Wall Street expectations.

Rite Aid disclosed a 55% tumble in fourth-quarter earnings, but the drug retailer’s adjusted profits easily exceeded expectations and management issued upbeat guidance.

Baxter unveiled plans to split itself into two separate companies, creating an independent biopharmaceuticals firm and a company focused on medical products.

Walgreen's earnings fell slightly in the second quarter, as lower sales of generic drugs weighed on margins.

Actavis said it will acquire Forest Laboratories in a cash-and-stock deal valued at $25 billion, creating a specialty pharmaceuticals heavyweight. 

Smith & Nephew inked a deal on Monday to buy medical device maker ArthroCare for $1.7 billion as it bets on sports medicine.